Breast cancer
Conditions
Interventions
None listed
Sponsors
KBCSG (Kinki Breast Cancer Study Group)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Breast cancer patient (a) planned to have three cycles or more of EC/FEC or AC regimen as pre/post-operative chemotherapy, (b) received at least one cycle, (c) had no progressive recurrence or metastasis 2) Patient was received chemotherapy including 75 mg/m2 or more of epirubicin, and 60 mg/m2 or more of doxorubicin in initial cycle 3) Patient was treated with either (a) Non-aprepitant therapy - patient was treated with a 5HT3-receptor antagonist and dexamethasone from the first cycle through the last cycle between January 2008 and December 2012, or (b) Aprepitant therapy (b-I) patient was treated with a 5HT3-receptor antagonist, dexamethasone, and aprepitant from the first cycle of chemotherapy between December 2009 and December 2012, (b-II) patient was treated with a 5HT3-receptor antagonist, dexamethasone, and aprepitant on the way since the second cycle of chemotherapy between December 2009 and December 2012 4) Day and dosage of anticancer drugs and antiemetic drugs can be identified in clinical record 5) Patient had never received any cancer chemotherapy other than the above EC/FEC or AC regimen with/without prior taxane treatment
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent of patients with 85% or more in relative dose intensity of epirubicin or doxorubicin | — |
Countries
Japan
Contacts
Public ContactTakahiro Nakayama
Osaka Medical Center for Cancer and Cardiovascular Disease Department of breast and endocrine surgery
Outcome results
None listed